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Background: The advantages of everolimus-eluting stents (EES) over paclitaxel-eluting stents (PES) have been established recently. However, 
less has been known about the advantages of EES over sirolimus-eluting stents (SES). Furthermore, the superiority of EES in the setting of acute 
myocardial infarction (AMI) remains unclear.
Methods: A total of 4175 AMI patients enrolled in Korea Acute Myocardial Infarction Registry (KAMIR) who received PES (n=1210), SES (n=1264), 
or EES (n=1701) were included. The composite clinical outcomes at 1 year were compared among the 3 groups. Target lesion failure (TLF) was 
defined as the composite of cardiac death, target lesion recurrent nonfatal myocardial infarction (Re-MI), or target lesion revascularization (TLR).
Results: The 3 groups had similar baseline clinical and procedural characteristics. The clinical outcomes at 1 year showed that compared to 
PES, SES had significantly lower incidences of TLR [1.8% vs 3.1%, P=0.034; adjusted odds ratio (OR) 0.55, 95% confidence interval (CI) 0.32-0.93, 
P=0.027] and TLF (7.9% vs 10.2%, P=0.043; adjusted OR 0.70, 95% CI 0.52-0.94, P=0.020). Compared to PES, EES showed significantly lower 
incidences of Re-MI (1.4% vs 2.7%, P=0.008; adjusted OR 0.44, 95% CI 0.24-0.79, P=0.006), TLR (1.2% vs 3.1%, P<0.001; adjusted OR 0.34, 
95% CI 0.19-0.62, P<0.001), TLF (6.1% vs 10.2%, P<0.001; adjusted OR 0.59, 95% CI 0.44-0.79, P<0.001), and stent thrombosis (0.4% vs 1.8%, 
P<0.001; adjusted OR 0.12, 95% CI 0.04-0.37, P<0.001). The comparisons between SES and EES revealed that although EES had significantly 
lower incidences of stent thrombosis (0.4% vs 1.1%, P=0.013) and TLF (6.1% vs 7.9%, P=0.048) as compared with SES in univariable analyses, the 
differences were no longer significant after multivariable Cox regression analyses.
Conclusions: EES and SES had similar safety and efficacy profiles in the setting of AMI. However, both EES and SES seem to be superior to PES in 
reducing target lesion failure.
